Aptamer against mannose-capped lipoarabinomannan inhibits virulent mycobacterium tuberculosis infection in mice and rhesus monkeys

Molecular Therapy

Volumn 22, Issue 5, 2014, Pages 940-951

  Pan, Qin ^a   Wang, Qilong ^a   Sun, Xiaoming ^a   Xia, Xianru ^a   Wu, Shimin ^b   Luo, Fengling ^a   Zhang, Xiao Lian ^a  

^a WUHAN UNIVERSITY   (China)

^b Wuhan Medical Treatment Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; APTAMER ZXL 1; GLYCOPROTEIN P 15095; MANNOSE; MANNOSE RECEPTOR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BCG VACCINE; EPITOPE; LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL LOAD; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DISSOCIATION CONSTANT; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUBERCULOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PATHOLOGY;

BACTERIA (MICROORGANISMS); MACACA MULATTA; MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; APTAMERS, NUCLEOTIDE; DENDRITIC CELLS; EPITOPES; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MANNOSE; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84899934276     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.31     Document Type: Article

References (40)

1. World Health Organization. (2011. The burden of disease caused by TB Global tuberculosis control 2011. (http://whqlibdoc.who.int/publications/2011/ 9789241564380-eng.pdf.
2. Svenson, S, Källenius, G, Pawlowski, A and Hamasur, B (2010. Towards new tuberculosis vaccines. Hum Vaccin 6: 309-317.
3. Colijn, C, Cohen, T, Ganesh, A and Murray, M (2011. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS ONE 6: e18327.
4. Gengenbacher, M and Kaufmann, SH (2012. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 36: 514-532.
5. Mortellaro, A, Robinson, L and Ricciardi-Castagnoli, P (2009. Spotlight on Mycobacteria and dendritic cells: will novel targets to fight tuberculosis emerge? EMBO Mol Med 1: 19-29.
6. Fratti, RA, Chua, J, Vergne, I and Deretic, V (2003. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc Natl Acad Sci USA 100: 5437-5442.
7. Mahon, RN, Sande, OJ, Rojas, RE, Levine, AD, Harding, CV and Boom, WH (2012. Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cell Immunol 275: 98-105.
8. Geijtenbeek, TB, Van Vliet, SJ, Koppel, EA, Sanchez-Hernandez, M, Vandenbroucke-Grauls, CM, Appelmelk, B et al. (2003. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 197: 7-17.
9. Ellington, AD and Szostak, JW (1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
10. Tuerk, C and Gold, L (1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
11. Mayer, G (2009. The chemical biology of aptamers. Angew Chem Int Ed Engl 48: 2672-2689.
12. Wheeler, LA, Trifonova, R, Vrbanac, V, Basar, E, McKernan, S, Xu, Z et al. (2011. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 121: 2401-2412.
13. Bouchard, PR, Hutabarat, RM and Thompson, KM (2010. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 50: 237-257.
14. Charlton, J and Smith, D (1999. Estimation of SELEX pool size by measurement of DNA renaturation rates. RNA 5: 1326-1332.
15. Torrelles, JB, Azad, AK and Schlesinger, LS (2006. Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J Immunol 177: 1805-1816.
16. Leteux, C, Chai, W, Loveless, RW, Yuen, CT, Uhlin-Hansen, L, Combarnous, Y et al. (2000. The cysteine-rich domain of the macrophage mannose receptor is a multispecific lectin that recognizes chondroitin sulfates A and B and sulfated oligosaccharides of blood group Lewis(a and Lewis(x types in addition to the sulfated N-glycans of lutropin. J Exp Med 191: 1117-1126.
17. Feinberg, H, Mitchell, DA, Drickamer, K and Weis, WI (2001. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294: 2163-2166.
18. Krohn, KA and Link, JM (2003. Interpreting enzyme and receptor kinetics: keeping it simple, but not too simple. Nucl Med Biol 30: 819-826.
19. McGreal, EP, Miller, JL and Gordon, S (2005. Ligand recognition by antigenpresenting cell C-type lectin receptors. Curr Opin Immunol 17: 18-24.
20. Shimizu, K and Fujii, S (2008. An adjuvant role of in situ dendritic cells (DCs in linking innate and adaptive immunity. Front Biosci 13: 6193-6201.
21. Balkow, S, Heinz, S, Schmidbauer, P, Kolanus, W, Holzmann, B, Grabbe, S et al. (2010. LFA-1 activity state on dendritic cells regulates contact duration with T cells and promotes T-cell priming. Blood 116: 1885-1894.
22. Chen, F, Zhou, J, Luo, F, Mohammed, AB and Zhang, XL (2007. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Biophys Res Commun 357: 743-748.
23. Hirayama, Y, Yoshimura, M, Ozeki, Y, Sugawara, I, Udagawa, T, Mizuno, S et al. (2009. Mycobacteria exploit host hyaluronan for efficient extracellular replication. PLoS Pathog 5: e1000643.
24. Okada, M, Kita, Y, Nakajima, T, Kanamaru, N, Hashimoto, S, Nagasawa, T et al. (2007. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA against tuberculosis using the cynomolgus monkey model of TB. Vaccine 25: 2990-2993.
25. Langermans, JA, Doherty, TM, Vervenne, RA, van der Laan, T, Lyashchenko, K, Greenwald, R et al. (2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
26. Qin, L, Zheng, R, Ma, Z, Feng, Y, Liu, Z, Yang, H et al. (2009. The selection and application of ssDNA aptamers against MPT64 protein in Mycobacterium tuberculosis. Clin Chem Lab Med 47: 405-411.
27. Rotherham, LS, Maserumule, C, Dheda, K, Theron, J and Khati, M (2012. Selection and application of ssDNA aptamers to detect active TB from sputum samples. PLoS ONE 7: e46862.
28. Nigou, J, Gilleron, M and Puzo, G (2003. Lipoarabinomannans: from structure to biosynthesis. Biochimie 85: 153-166.
29. Mishra, AK, Driessen, NN, Appelmelk, BJ and Besra, GS (2011. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction. FEMS Microbiol Rev 35: 1126-1157.
30. Rescigno, M, Martino, M, Sutherland, CL, Gold, MR and Ricciardi-Castagnoli, P (1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med 188: 2175-2180.
31. Banchereau, J and Steinman, RM (1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
32. Shortman, K and Liu, YJ (2002. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2: 151-161.
33. Keefe, AD, Pai, S and Ellington, A (2010. Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550.
34. US Food and Drug Administration. (2004. Macugen, Pegaptanib Sodium. FDA Pharmacology Review. (http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21- 756-Macugen-pharmr.pdf
35. World Health Organization. (2006. Treatment of tuberculosis: guidelines for national programmes, 4th edition (WHO/HTM/TB/2009.420.
36. Jiang, T, Zhan, Y, Sun, M, Liu, S, Zang, S, Ma, Y et al. (2011. The novel responses of ethambutol against Mycobacterium smegmatis mc155 Revealed by proteomics analysis. Curr Microbiol 62: 341-345.
37. Ma, Y, Chen, HD, Wang, Y, Wang, Q, Li, Y, Zhao, Y et al. (2011. Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection. Microbes Infect 13: 1099-1110.
38. Ma, Y, Chen, H, Wang, Q, Luo, F, Yan, J and Zhang, XL (2009. IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells. Eur J Immunol 39: 3357-3368.
39. Singer, K, Morris, DL, Oatmen, KE, Wang, T, DelProposto, J, Mergian, T et al. (2013. Neuropeptide Y is produced by adipose tissue macrophages and regulates obesityinduced inflammation. PLoS ONE 8: e57929.
40. Li, DY, Gu, C, Min, J, Chu, ZH and Ou, QJ (2012. Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 4: 131-134.